Literature DB >> 6478436

Sarcoma arising in a residual testicular teratoma after cytoreductive chemotherapy.

A D Ahlgren, C R Simrell, T J Triche, R Ozols, S H Barsky.   

Abstract

A case of testicular teratoma metastasized to the retroperitoneum and after cytoreductive chemotherapy was noted to contain areas of frank sarcoma. Sarcomatous areas included embryonal rhabdomyosarcoma with a pattern of sarcoma botyroides, alveolar rhabdomyosarcoma, and fibrosarcoma. These areas differed markedly from areas of immature teratoma, which composed the remainder of the retroperitoneal lesion and which also characterized the primary tumor. These sarcomatous areas were characterized by numerous mitoses, marked cellular pleomorphism and diagnostic histologic, ultrastructural, and immunocytochemical features. Residual germ cell tumors following cytoreductive chemotherapy are traditionally categorized as teratoma only or teratoma with embryonal carcinoma or choriocarcinoma for therapeutic and prognostic reasons. This case does not conform to this simple categorization and raises serious questions concerning subsequent therapeutic decisions.

Entities:  

Mesh:

Year:  1984        PMID: 6478436     DOI: 10.1002/1097-0142(19841101)54:9<2015::aid-cncr2820540939>3.0.co;2-b

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  13 in total

Review 1.  Teratoma with somatic-type malignant components of the testis. A review and an update.

Authors:  Gregor Mikuz; Maurizio Colecchia
Journal:  Virchows Arch       Date:  2012-05-24       Impact factor: 4.064

2.  Remission of recurrent mature teratoma with interferon therapy.

Authors:  D Ornadel; A Wilson; C Trask; J Ledermann
Journal:  J R Soc Med       Date:  1995-09       Impact factor: 5.344

3.  Findings in lymph nodes of patients with germ cell tumours after chemotherapy and their relation to prognosis.

Authors:  R J Zuk; B J Jenkins; J E Martin; R T Oliver; S I Baithun
Journal:  J Clin Pathol       Date:  1989-10       Impact factor: 3.411

Review 4.  Diagnosis and treatment of patients with testicular germ cell cancer.

Authors:  J T Hartmann; L Kanz; C Bokemeyer
Journal:  Drugs       Date:  1999-08       Impact factor: 9.546

5.  Growing teratoma syndrome of ovary.

Authors:  Roopa Hariprasad; Lalit Kumar; Deepa Janga; Sunesh Kumar; Malini Vijayaraghavan
Journal:  Int J Clin Oncol       Date:  2008-02-29       Impact factor: 3.402

6.  Rhabdomyosarcomas developing in association with mediastinal germ cell tumours.

Authors:  C Caballero; S Gomez; X Matias-Guiu; J Prat
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1992

7.  Development and characterization of two equine formulations towards SARS-CoV-2 proteins for the potential treatment of COVID-19.

Authors:  Guillermo León; María Herrera; Mariángela Vargas; Mauricio Arguedas; Andrés Sánchez; Álvaro Segura; Aarón Gómez; Gabriela Solano; Eugenia Corrales-Aguilar; Kenneth Risner; Aarthi Narayanan; Charles Bailey; Mauren Villalta; Andrés Hernández; Adriana Sánchez; Daniel Cordero; Daniela Solano; Gina Durán; Eduardo Segura; Maykel Cerdas; Deibid Umaña; Edwin Moscoso; Ricardo Estrada; Jairo Gutiérrez; Marcos Méndez; Ana Cecilia Castillo; Laura Sánchez; Ronald Sánchez; José María Gutiérrez; Cecilia Díaz; Alberto Alape
Journal:  Sci Rep       Date:  2021-05-10       Impact factor: 4.379

8.  Pediatric Ovarian Growing Teratoma Syndrome.

Authors:  Rebecca M Rentea; Aaron Varghese; Atif Ahmed; Alexander Kats; Michelle Manalang; Tazim Dowlut-McElroy; Richard J Hendrickson
Journal:  Case Rep Surg       Date:  2017-06-01

9.  Pure Testicular Seminoma Relapsing Late with Somatic Type Malignancy.

Authors:  Klaus-Peter Dieckmann; Petra Anheuser; Ralf Gehrckens; Waldemar Wilczak; Guido Sauter; Doris Höflmayer
Journal:  Case Rep Oncol Med       Date:  2017-03-07

10.  Growing teratoma syndrome of the ovary showing three patterns of metastasis: a case report.

Authors:  Kiyosumi Shibata; Hiroaki Kajiyama; Fumitaka Kikkawa
Journal:  Case Rep Oncol       Date:  2013-11-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.